Theravance Biopharma to Report Second Quarter 2024 Financial Results on August 5, 2024
Theravance Biopharma(TBPH) Prnewswire·2024-07-22 10:00Conference Call Information A replay of the webcast will be available on Theravance Biopharma's website for 30 days through September 4, 2024. Theravance Biopharma, Inc.'s focus is to deliver Medicines that Make a Difference® in people's lives. In pursuit of its purpose, Theravance Biopharma leverages decades of expertise, which has led to the development of FDA-approved YUPELRI® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease ...